Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00884715 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
A Phase 1 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00884715: Clinical Trial Phase 1 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00884715 is a Phase 1 study that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00884715, a Phase 1 study, was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.
Interventions
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00884715
The ClinicalTrials.gov registry entry for NCT00884715 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Octreotide is the first listed.
NCT00884715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00884715 about?
NCT00884715 is a clinical study titled "Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome". Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.
What is the current status of trial NCT00884715?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00884715?
The interventions under investigation include: Octreotide (DRUG).
Who is sponsoring clinical trial NCT00884715?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.